Condition: Osteosarcoma · Sponsor: MedPacto, Inc.
MP-VAC-209 is a Phase I/II, open label, single arm, multi-center study to assess safety, tolerability, and antitumor activity of vactosertib as a single agent in adolescents and adults with recurrent, refractory, or progressive osteosarcoma. Vactosertib is given orally, twice a day, to people 12 years of age and older who meet the criteria for study enrollment.
This description comes directly from the study's public registry record.
Kristen VanHeyst, DO · (216) 844-3345 · Kristen.VanHeyst@UHhospitals.org
Always discuss trial participation with your own doctor first.
| UH Rainbow Babies & Children's Hospital | Cleveland, Ohio, United States | Recruiting |
| National Cancer Center | Gyeonggi-do, South Korea | Recruiting |
| Korea Institute of Radiological & Medical Sciences | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05588648